Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service spinal cord & DRG stimulation cases in Washington: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (170 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 16 | 537 | 37% |
| 2020 | 13 | 427 | 40% |
| 2021 | 15 | 479 | 43% |
| 2022 | 13 | 487 | 46% |
| 2023 | 20 | 470 | 50% |
| 2024 | 15 | 398 | 54% |
| 2025 from claims | – | 441 357–518 | 54% |
| 2026 forecast | – | 447 350–562 | 54% |
| 2027 forecast | – | 448 332–592 | 55% |
| 2028 forecast | – | 449 318–620 | 56% |
| 2029 forecast | – | 450 306–645 | 57% |
| 2030 forecast | – | 450 295–668 | 57% |
Permanent stimulator implants, counted by the generator; trial and permanent leads and revisions are fetched but not counted as cases. Professional codes (what the surgeon bills): CPT 63685.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 77% of the cases CMS names in Washington; 11 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 24% hospital outpatient, 76% surgery center. The share outside the hospital has moved +20 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Hospital outpatient | Surgery center |
|---|---|---|
| 2026 · ~450 | ~100 | ~350 |
| 2027 · ~450 | ~98 | ~350 |
| 2028 · ~450 | ~97 | ~350 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 78% (76% in 2025), hospital outpatient about 22% (24% in 2025). More of these cases each year are decided in surgery centers, where the surgeons often own the center and weigh price and turnaround.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 48 | 1,564−4.8%/yr | −4.8%/yr | 0.4 | 89% | 1,890 in 2030+3.2%/yr |
| Arizona | 28 | 930+0.9%/yr | +0.9%/yr | 1.2 | 78% | 1,060 in 2030+2.2%/yr |
| Utah | 9 | 400+6.6%/yr | +6.6%/yr | 1.7 | 75% | 450 in 2030+2.2%/yr |
| Nevada | 6 | 353−6%/yr | −6%/yr | 1.1 | 95% | 380 in 2030+1%/yr |
| Oregon | 11 | 336−6%/yr | −6%/yr | 0.7 | 95% | 480 in 2030+6.2%/yr |
| Colorado | 6 | 257−4.5%/yr | −4.5%/yr | 0.5 | 65% | 390 in 2030+7.1%/yr |
| Idaho | 7 | 175−2.7%/yr | −2.7%/yr | 0.8 | 46% | 200 in 2030+1.9%/yr |
| Montana | 3 | 110−6%/yr | −6%/yr | 0.6 | 17% | 90 in 2030−3%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 75 | 4,700−0.3%/yr | −0.3%/yr | 5.90.6× | 77% | 5,550 in 2030+2.8%/yr |
| Peripheral nerve stimulation & intrathecal pumps | 8 | 573+7.4%/yr | +7.4%/yr | 0.70.7× | 55% | 1,090 in 2030+11%/yr |
Spinal cord & DRG stimulation in every state, and its device makers · Every procedure market in Washington · Every state · Compare with California
Boston Scientific leads with 26% of company spending on these surgeons in 2025, +11 pts on 2024.
In 2025, 9 companies reported engagement with Washington’s surgeons worth $155K in consulting, speaking, meals and travel tied to these products, about $10K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 63 clearances and approvals in the category, 4 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.